|Dr. Christopher J. Kirk||Co-Founder, Pres, Chief Scientific Officer & Director||514.57k||N/A||1972|
|Mr. John Franklin Fowler||Co-Founder, CEO & Director||N/A||N/A||1972|
|Dr. Jack Taunton||Co-Founder||N/A||N/A||N/A|
|Mr. Marc L. Belsky||CFO & Sec.||N/A||N/A||1955|
|Michael Wolfe||Director of Fin. & Operations||N/A||N/A||N/A|
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California.
Kezar Life Sciences, Inc.’s ISS Governance QualityScore as of February 3, 2020 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.